{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:37:25Z","timestamp":1786617445223,"version":"build-2736575974"},"posted":{"date-parts":[[2026,8,10]]},"group-title":"Neurology","reference-count":42,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 NS132022"],"award-info":[{"award-number":["R01 NS132022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Prions@Broad"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background and Objectives<\/jats:title>\n                  <jats:p>Prion disease is an untreatable, typically rapidly progressive dementia. New drug candidates designed to lower prion protein are now entering clinical trials. To support future pivotal trials, we sought to assemble and analyze a public dataset of natural history data characterizing the symptomatic course of prion disease in order to provide a quantitative basis for modelling and rational trial design.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We extracted data from medical publications between 2000 and 2024 reporting on n\u22655 prion disease patients. Information about demographics, ascertainment, and clinical milestones, such as time from onset to death, akinetic mutism, diagnostic testing and outcomes, were extracted for aggregate cohorts of \u22652 patients and individual patient-level data (PLD). We computed summary statistics of cohorts and PLD, visualized survival through forest plots and Kaplan-Meier curves, analyzed covariates regarding survival, and identified biases and heterogeneity within the literature.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 245 included publications we extracted 418 aggregate cohort medians and 1,400 rows of individual PLD. 90% of cohorts and 91% of individual patients had symptom-to-death milestones, while only 7% and 11% had a time interval from a clinical presentation milestone to death, respectively. Symptom-to-death intervals varied as much as 3.2-fold even between cohorts of the same histopathologic subtype, and akinetic mutism occurred 73% sooner than death when both endpoints were reported (N=53). Indicators of disease severity, such as a cognitive test, were rarely present in either aggregate data (11%) or PLD (6%).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Data routinely reported in publications can quantify diagnostic delay and covariates affecting survival time, but are limited in ability to inform pivotal trial design because most such data are aggregated, cross-sectional, lack indicators of disease severity, and present timelines beginning with onset rather than more relevant clinical milestones, such as diagnosis, that may better reflect the moment of potential for trial enrollment. There is a need for clinical data to report milestones such as intervals from diagnosis to death, for longitudinal cognitive and functional scores, and for deposition of publicly accessible PLD.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.08.07.26359973","type":"posted-content","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:00:17Z","timestamp":1786377617000},"source":"Crossref","is-referenced-by-count":0,"title":["Aggregation and analysis of 25 years of prion disease natural history extracted from published literature"],"prefix":"10.64898","author":[{"given":"Leo M.H.","family":"Xu","sequence":"first","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Sprague","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-2702","authenticated-orcid":false,"given":"Sonia M","family":"Vallabh","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA"},{"name":"McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA"},{"name":"Department of Neurology, Harvard Medical School, Boston, MA, 02115, USA"},{"name":"Prion Alliance, Cambridge, MA, 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2206-1608","authenticated-orcid":false,"given":"Eric Vallabh","family":"Minikel","sequence":"additional","affiliation":[{"name":"Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA"},{"name":"McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA"},{"name":"Department of Neurology, Harvard Medical School, Boston, MA, 02115, USA"},{"name":"Prion Alliance, Cambridge, MA, 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026081303150659000_2026.08.07.26359973v1.1","unstructured":"U.S. Food and Drug Administration. Rare Diseases: Natural History Studies for Drug Development. Guidance for Industry. [Internet]. 2019 [cited 2026 Feb 12]. Available from: https:\/\/www.fda.gov\/media\/122425\/download"},{"key":"2026081303150659000_2026.08.07.26359973v1.2","unstructured":"U.S. Food and Drug Administration. Framework for FDA\u2019s Real-world Evidence Program [Internet]. 2018 [cited 2026 Feb 12]. Available from: https:\/\/www.fda.gov\/media\/120060\/download"},{"key":"2026081303150659000_2026.08.07.26359973v1.3","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3021"},{"key":"2026081303150659000_2026.08.07.26359973v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30403-X"},{"key":"2026081303150659000_2026.08.07.26359973v1.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp3043"},{"key":"2026081303150659000_2026.08.07.26359973v1.6","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-132465"},{"key":"2026081303150659000_2026.08.07.26359973v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00497-y"},{"key":"2026081303150659000_2026.08.07.26359973v1.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a9f3b4"},{"key":"2026081303150659000_2026.08.07.26359973v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70307-7"},{"key":"2026081303150659000_2026.08.07.26359973v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70307-7"},{"key":"2026081303150659000_2026.08.07.26359973v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt048"},{"key":"2026081303150659000_2026.08.07.26359973v1.12","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad267"},{"key":"2026081303150659000_2026.08.07.26359973v1.13","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-025-00884-3"},{"key":"2026081303150659000_2026.08.07.26359973v1.14","doi-asserted-by":"publisher","DOI":"10.1080\/19336896.2025.2565204"},{"key":"2026081303150659000_2026.08.07.26359973v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00082-5"},{"key":"2026081303150659000_2026.08.07.26359973v1.16","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12133"},{"key":"2026081303150659000_2026.08.07.26359973v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac201"},{"key":"2026081303150659000_2026.08.07.26359973v1.18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4885"},{"key":"2026081303150659000_2026.08.07.26359973v1.19","unstructured":"Ionis Pharmaceuticals, Inc. A Phase 1\/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients With Prion Disease [Clinical trial registration] [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Jul 2]. Clinical trial registration no.: NCT06153966. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06153966"},{"key":"2026081303150659000_2026.08.07.26359973v1.20","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000196440.00297.67"},{"key":"2026081303150659000_2026.08.07.26359973v1.21","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180123"},{"key":"2026081303150659000_2026.08.07.26359973v1.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24833"},{"key":"2026081303150659000_2026.08.07.26359973v1.23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010086"},{"key":"2026081303150659000_2026.08.07.26359973v1.24","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160740"},{"key":"2026081303150659000_2026.08.07.26359973v1.25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab350"},{"key":"2026081303150659000_2026.08.07.26359973v1.26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1071"},{"key":"2026081303150659000_2026.08.07.26359973v1.27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007745"},{"key":"2026081303150659000_2026.08.07.26359973v1.28","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.03.25337271"},{"key":"2026081303150659000_2026.08.07.26359973v1.29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209506"},{"key":"2026081303150659000_2026.08.07.26359973v1.30","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad101"},{"key":"2026081303150659000_2026.08.07.26359973v1.31","unstructured":"NPDPSC Table of Cases Examined | Pathology | School of Medicine | Case Western Reserve University [Internet]. 2024 [cited 2024 Oct 29]. Available from: https:\/\/case.edu\/medicine\/pathology\/research\/national-prion-disease-pathology-surveillance-center\/surveillance\/tables-cases-examined"},{"key":"2026081303150659000_2026.08.07.26359973v1.32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5169"},{"issue":"2","key":"2026081303150659000_2026.08.07.26359973v1.33","first-page":"2","article-title":"Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects","volume":"46","year":"1999","journal-title":"Ann Neurol"},{"key":"2026081303150659000_2026.08.07.26359973v1.34","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh249"},{"key":"2026081303150659000_2026.08.07.26359973v1.35","doi-asserted-by":"publisher","DOI":"10.2188\/jea.je20100085"},{"key":"2026081303150659000_2026.08.07.26359973v1.36","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq216"},{"key":"2026081303150659000_2026.08.07.26359973v1.37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2026081303150659000_2026.08.07.26359973v1.38","doi-asserted-by":"publisher","DOI":"10.1101\/2024.11.12.623215"},{"key":"2026081303150659000_2026.08.07.26359973v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2017.01.021"},{"key":"2026081303150659000_2026.08.07.26359973v1.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1713258"},{"key":"2026081303150659000_2026.08.07.26359973v1.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2026081303150659000_2026.08.07.26359973v1.42","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1686"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.08.07.26359973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:15:14Z","timestamp":1786616114000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.08.07.26359973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":42,"URL":"https:\/\/doi.org\/10.64898\/2026.08.07.26359973","relation":{},"subject":[],"published":{"date-parts":[[2026,8,10]]},"subtype":"preprint"}}